CHRS
Coherus Oncology, Inc.
Biotechnology
Market Cap$212M
5Y Perf.-90.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CHRS vs HCM
Revenue, margins, valuation, and 5-year total return — side by side.
HCM
HUTCHMED (China) Limited
Drug Manufacturers - Specialty & Generic
Market Cap$2.31B
5Y Perf.-38.4%
CHRS vs HCM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CHRS | HCM |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $212M | $2.31B |
| Revenue (TTM) | $42M | $602M |
| Net Income (TTM) | $168M | $467M |
| Gross Margin | -37.3% | 8.9% |
| Operating Margin | -429.5% | -3.3% |
| Forward P/E | 1.2x | 42.0x |
| Total Debt | $1M | $90M |
| Cash & Equiv. | $89M | $154M |
CHRS vs HCM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CHRS
HCM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 100 | 9.4 | -90.6% |
| HUTCHMED (China) Li… (HCM) | 100 | 61.6 | -38.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHRS vs HCM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHRS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. HUTCHMED (China) Limited is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CHRS
Coherus Oncology, Inc.
The Value Play
CHRS carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (1.2x vs 42.0x)
- 398.4% margin vs HCM's 77.5%
- +88.2% vs HCM's -9.6%
Best for: value and quality
HCM
HUTCHMED (China) Limited
The Income Pick
HCM is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.66
- Rev growth -24.8%, EPS growth -63.3%, 3Y rev CAGR 21.0%
- -2.7% 10Y total return vs CHRS's -90.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HCM | -24.8% revenue growth vs CHRS's -84.2% |
| Value | CHRS | Lower P/E (1.2x vs 42.0x) |
| Quality / Margins | CHRS | 398.4% margin vs HCM's 77.5% |
| Stability / Safety | HCM | Beta 0.66 vs CHRS's 2.29 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CHRS | +88.2% vs HCM's -9.6% |
| Efficiency (ROA) | CHRS | 42.4% ROA vs HCM's 30.6% |
CHRS vs HCM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2023
CHRS vs HCM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHCMLAGGINGCHRS
CHRSCoherus Oncology, Inc.
1leads
HCMHUTCHMED (China) Limi…
4leads
6 Total Categories
CATEGORYLEADERvs CHRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HCM5/6
Valuation MetricsMultiples, price ratios, and targets
HCM2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CHRS6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
HCM4/6
Risk & VolatilityBeta, volatility, and downside exposure
HCM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HCM leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCM is the larger business by revenue, generating $602M annually — 14.3x CHRS's $42M. Profitability is closely matched — net margins range from 4.0% (CHRS) to 77.5% (HCM). On growth, HCM holds the edge at -9.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| RevenueTrailing 12 months | $42M | $602M |
| EBITDAEarnings before interest/tax | -$184M | -$7M |
| Net IncomeAfter-tax profit | $168M | $467M |
| Free Cash FlowCash after capex | -$139M | -$50M |
| Gross MarginGross profit ÷ Revenue | -37.3% | +8.9% |
| Operating MarginEBIT ÷ Revenue | -4.3% | -3.3% |
| Net MarginNet income ÷ Revenue | +4.0% | +77.5% |
| FCF MarginFCF ÷ Revenue | -3.3% | -8.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -76.5% | -9.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.5% | +16.6% |
HCM leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
HCM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
At 1.2x trailing earnings, CHRS trades at a 98% valuation discount to HCM's 61.0x P/E.
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| Market CapShares × price | $212M | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $125M | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | 1.22x | 61.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 42.03x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5.03x | 3.66x |
| Price / BookPrice ÷ Book value/share | 3.45x | 3.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
HCM leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CHRS leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CHRS delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $46 for HCM. CHRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCM's 0.12x. On the Piotroski fundamental quality scale (0–9), CHRS scores 4/9 vs HCM's 3/9, reflecting mixed financial health.
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| ROE (TTM)Return on equity | +7.9% | +46.4% |
| ROA (TTM)Return on assets | +42.4% | +30.6% |
| ROICReturn on invested capital | — | -5.2% |
| ROCEReturn on capital employed | -127.8% | -4.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.12x |
| Net DebtTotal debt minus cash | -$87M | -$64M |
| Cash & Equiv.Liquid assets | $89M | $154M |
| Total DebtShort + long-term debt | $1M | $90M |
| Interest CoverageEBIT ÷ Interest expense | -28.88x | -15.22x |
CHRS leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
HCM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HCM five years ago would be worth $4,958 today (with dividends reinvested), compared to $1,207 for CHRS. Over the past 12 months, CHRS leads with a +88.2% total return vs HCM's -9.6%. The 3-year compound annual growth rate (CAGR) favors HCM at -4.7% vs CHRS's -40.1% — a key indicator of consistent wealth creation.
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| YTD ReturnYear-to-date | +27.7% | -1.6% |
| 1-Year ReturnPast 12 months | +88.2% | -9.6% |
| 3-Year ReturnCumulative with dividends | -78.5% | -13.5% |
| 5-Year ReturnCumulative with dividends | -87.9% | -50.4% |
| 10-Year ReturnCumulative with dividends | -90.9% | -2.7% |
| CAGR (3Y)Annualised 3-year return | -40.1% | -4.7% |
HCM leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
HCM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HCM is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than CHRS's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.29x | 0.66x |
| 52-Week HighHighest price in past year | $2.62 | $19.50 |
| 52-Week LowLowest price in past year | $0.71 | $12.91 |
| % of 52W HighCurrent price vs 52-week peak | +66.9% | +68.9% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 34.2 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 31K |
HCM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CHRS as "Buy" and HCM as "Buy". Consensus price targets imply 244.0% upside for CHRS (target: $6) vs 30.3% for HCM (target: $18).
| Metric | CHRSCoherus Oncology,… | HCMHUTCHMED (China) … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.02 | $17.50 |
| # AnalystsCovering analysts | 16 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% |
Insufficient data to determine a leader in this category.
Key Takeaway
HCM leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). CHRS leads in 1 (Profitability & Efficiency).
Best OverallHUTCHMED (China) Limited (HCM)Leads 4 of 6 categories
Loading custom metrics...
CHRS vs HCM: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CHRS or HCM a better buy right now?
For growth investors, HUTCHMED (China) Limited (HCM) is the stronger pick with -24.
8% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHRS or HCM?
On trailing P/E, Coherus Oncology, Inc.
(CHRS) is the cheapest at 1. 2x versus HUTCHMED (China) Limited at 61. 0x.
03Which is the better long-term investment — CHRS or HCM?
Over the past 5 years, HUTCHMED (China) Limited (HCM) delivered a total return of -50.
4%, compared to -87. 9% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: HCM returned -2. 7% versus CHRS's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHRS or HCM?
By beta (market sensitivity over 5 years), HUTCHMED (China) Limited (HCM) is the lower-risk stock at 0.
66β versus Coherus Oncology, Inc. 's 2. 29β — meaning CHRS is approximately 246% more volatile than HCM relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 12% for HUTCHMED (China) Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — CHRS or HCM?
By revenue growth (latest reported year), HUTCHMED (China) Limited (HCM) is pulling ahead at -24.
8% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -63. 3% for HUTCHMED (China) Limited. Over a 3-year CAGR, HCM leads at 21. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CHRS or HCM?
Coherus Oncology, Inc.
(CHRS) is the more profitable company, earning 398. 4% net margin versus 6. 0% for HUTCHMED (China) Limited — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCM leads at -6. 9% versus -429. 5% for CHRS. At the gross margin level — before operating expenses — HCM leads at 44. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CHRS or HCM more undervalued right now?
Analyst consensus price targets imply the most upside for CHRS: 244.
0% to $6. 02.
08Which pays a better dividend — CHRS or HCM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CHRS or HCM better for a retirement portfolio?
For long-horizon retirement investors, HUTCHMED (China) Limited (HCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66)). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCM: -2. 7%, CHRS: -90. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CHRS and HCM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHRS is a small-cap deep-value stock; HCM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CHRS: -76.5% · HCM: -9.2%)Net Margin>
%
(CHRS: 398.4% · HCM: 77.5%)P/E Ratio<
x
(CHRS: 1.2x · HCM: 61.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.